RESOLVING THE LEDGER
RESOLVING THE LEDGER
This is not a single article. It's every outletcovering this one event, gathered in one place — read AIPROPX's summary, see where the sources line up, then open any report at its origin.
By AIPROPX Editorial Desk · Published · Updated
Everything reported about this story, gathered from 6 sources. Read the summary below, then tap any source to open that report.
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
Summary indexed by AIPROPX from KSL’s reporting — the full article is one click away. Open at source →
6 outlets are covering this. Resolve the ledger to read what they collectively report — the common thread, in plain terms.
Every report on this story — read the summary of each, then open any at its source. AIPROPX summarizes and links; it never reproduces the original.
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
Read this report
The FDA approved a life-extending treatment for advanced pancreatic cancer from Revolution Medicines that is the first to attack a genetic cause
Read this report
Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more.
Read this reportPancreatic cancer is considered one of the hardest to treat and most serious forms of cancer
Read this reportAn original, deterministic readout — composed only from the computed coverage facts on this page. No interpretation, no rating; figures only.
AIPROPX has consolidated 6 reports from 6 outlets into a single canonical entry on “Revolution Medicines gets FDA nod for targeted pancreatic cancer drug.” The covered outlets are based across 2 regions — Other and US.
The earliest report in this entry came from Scientific American (Aug 26, 2026, 16:00 UTC); the most recent came from Northeast Times (Aug 28, 2026, 02:24 UTC).
Comparing the wording across sources, 4 named entities are referenced by multiple outlets and the phrase recurring most across the coverage is “pancreatic cancer”.
5 statements are carried by only one outlet within this set and are not echoed by the others.
Every figure above is a direct count of real published articles. AIPROPX indexes and compares the original reporting — it never rewrites, rates, or editorializes — and each publisher’s full article is always one click away.
Generated by AIPROPX from the source counts above. AIPROPX indexes and resolves coverage; the original publishers are credited and linked at origin in every report.
Coverage from 6 independent outlets across 2 regions — each view opens on its own page.
AIPROPX — “Revolution Medicines gets FDA nod for targeted pancreatic cancer drug” · https://www.aipropx.com/story/1fe56c0ecda87e5bd5b296e8b8f69ec9
Other events being covered across multiple sources right now.
Friendship man charged with assault on officer during drug enforcement operation
3 outletsCyclospora Lettuce Update: FDA Issues Strongest Warning, Adds 3 More States
3 outlets68 Years Later, Katz Drug Store Sit-In Leaves Lasting Legacy in Oklahoma
3 outletsGreen Bay area gets its first 24/7 emergency pet hospital in over a year
3 outletsDelta Flight From LA To Boston Lands In Detroit As Captain Gets Sick: "I Am The One Who Is Ill
45 outletsPartial lunar eclipse captures hearts